Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.41 |
| ▸ | PRKDC | P78527 | 11/20 | 0.41 |
| ▸ | ATR | Q13535 | 10/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 10/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | SERPINA2 | P20848 | 6/20 | 0.40 |
| ▸ | MTOR | P42345 | 6/20 | 0.40 |
| ▸ | ATM | Q13315 | 5/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070628 | 0.90 | PIK3CA (0.46) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL17243957 | 0.88 | PIK3CA (0.47) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL807838 | 0.88 | PIK3CA (0.44) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL10070629 | 0.86 | PIK3CA (0.44) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL15131806 | 0.86 | PIK3CB (0.47) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL807983 | 0.86 | PIK3CA (0.43) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL17243665 | 0.85 | PIK3CA (0.42) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL796867 | 0.85 | PIK3CA (0.43) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL807819 | 0.83 | PIK3CA (0.43) | PIK3CAPIK3CBPRKDCATRATRIP | |
| SCHEMBL807988 | 0.83 | GRIN1 (0.42) | PIK3CAPIK3CBPRKDCATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | PIK3CA 1962/4885PIK3CB 1750/4885PRKDC 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.